AI assistant
DIMERIX LIMITED — Capital/Financing Update 2012
Mar 22, 2012
64804_rns_2012-03-22_cc364627-ea45-4b87-8623-58da6d6de8c8.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [228 x 84] intentionally omitted <==
23 March 2012
ASX Limited Company Announcements Office Level 4, Stock Exchange Centre 20 Bridge Street SYDNEY NSW 2000
Dear Sir/Madam
MARGIN LOAN UPDATE
Sun Biomedical Limited (ASX: SBN) wishes to advise that settlement of the loan advanced pursuant to the Margin Loan Agreement it entered into on 31 July 2011 has now been completed.
As previously announced, the loan was an interest bearing loan pursuant to which SBN advanced $291,236 to the Borrower. SBN is pleased to confirm that $362,733.22 in respect of the principal, interest and costs has been repaid to it by the Borrower via a cash payment of $208,794.92 and the transfer of 10,995,593 MAR shares at a deemed issue price of $0.014 each.
SBN is continuing to investigate and assess a number of potential investment opportunities that will provide the Company and shareholders with a commercial return.
Yours faithfully
==> picture [117 x 48] intentionally omitted <==
Terry Cuthbertson Chairman
Sun Biomedical Investor Communications Limited Computershare T: +61 1300 850 505 | F: +61 3 9473 2500 | ABN 18 001 285 230 E: [email protected]
ASX:SBN www.sunbiomed.com